Tuesday, November 5, 2024
HomeStock MarketGilead Trodelvy with Merck’s Keytruda controls lung most cancers

Gilead Trodelvy with Merck’s Keytruda controls lung most cancers


Justin Sullivan/Getty Photos Information

Gilead (NASDAQ:GILD) introduced Sunday that its antibody-drug conjugate Trodelvy and Merck’s (NYSE:MRK) anti-PD-1 immunotherapy Keytruda lower tumor dimension in beforehand untreated non-small cell lung most cancers (NSCLC), the most common type of lung most cancers.

Forward of a presentation on the World Convention



Supply hyperlink

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments